CPC A61K 35/28 (2013.01) [C07K 14/475 (2013.01); C07K 14/49 (2013.01); C07K 14/521 (2013.01); C07K 14/5415 (2013.01); C07K 14/5437 (2013.01); A61K 38/00 (2013.01); A61P 25/16 (2018.01)] | 9 Claims |
1. A pharmaceutical composition comprising an isolated exosome population derived from mesenchymal stem cells secreting-neurotrophic factors (MSC-NTF cells), said isolated exosomes comprising an increased quantity of at least one cargo protein, wherein said at least one cargo protein comprises a neurotrophic factor (NTF), compared with the quantity of said at least one cargo protein in an isolated exosome population derived from control non-differentiated MSCs, wherein said NTF comprises a leukemia inhibitory factor (LIF) protein, a vascular endothelial growth factor A (VEGFA) protein, or a growth differentiation factor 15 (GDF15) protein, or any combination thereof,
wherein said MSC-NTF cells are cultured in a three-dimensional (3D) bioreactor in no shear stress, and propagated in Dulbecco's Modified Eagle's Medium (DMEM) comprising platelet lysate,
wherein said exosomes are purified by removing the culture media from the three-dimensional (3D) bioreactor, filtered using a 1.2 μM filter and Tangential Flow Filtration (TFF), and further filtered through a 0.22 μM filter.
|